Small Cell Lung Cancer (SCLC)

Latest News

Factors including age, gender, and facility type may influence the likelihood of pain referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
Demographic Factors May Impact Pain Management Referrals in SCLC/NSCLC

March 15th 2023

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.
IO/Chemo Associated With Higher Toxicity Risk in ES-SCLC

March 14th 2023

A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Glasgow Prognostic Score May Predict Atezolizumab/Chemo Outcomes in SCLC

February 22nd 2023

Patients 70 years or older with limited stage small cell lung cancer appear to tolerate concurrent thoracic chemoradiotherapy and have similar disease control rates as younger patients.
Concurrent CRT Garners Disease Control, Safety in SCLC Regardless of Age

February 13th 2023

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.
BMS-986012 ± Nivolumab Appears Well-Tolerated in Relapsed/Refractory SCLC

January 17th 2023

Video Interviews
Podcasts
In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.
In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.
Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.
In the first episode of a 4-part series, CancerNetwork® spoke with Wade Iams, MD, about the various first-line treat options that are available for patients with small cell lung cancer.

More News